What are the odds we get an heir to Paxlovid?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we look at some promising, but early, gene therapy data from Lexeo Therapeutics, examine Medicare’s new price negotiation rules and their impact on innovation, and more.

Lexeo’s gene therapy for rare heart disease looks promising

Lexeo Therapeutics is developing a gene therapy meant to prevent deadly heart complications in patients with Friedreich’s ataxia, a rare genetic disorder of the heart. The results are early and inconclusive but promising — and Lexeo is optimistic that it could win FDA approval, after another study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In